Market Frolics & Future Prospects

Iovance Biotherapeutics, a name to conjure with, experienced a positively ripping good climb of 32% on the back of some encouraging sarcoma trial data. And Advanced Micro Devices, not to be outdone, found itself on the upswing, thanks to whispers of a new AI chip arrangement with Meta Platforms – a decidedly clever bit of business, that. In the realm of everyday staples, J.M. Smucker, a firm built on solid foundations, outperformed expectations following a commendation from the Bank of America, while General Mills, alas, lagged somewhat after a less-than-enthusiastic assessment.








